In short
Clinical trials are studying RUBELLA VIRUS WISTAR RA 27/3 STRAIN (LIVE, ATTENUATED) PRODUCED IN HUMAN DIPLOID (MRC-5) CELLS as part of vaccines given to children. The trials look at immune response, safety, and how well vaccination works in healthy young children and in children and adolescents after cancer treatment.
Key points
- Clinical trials investigating RUBELLA VIRUS WISTAR RA 27/3 STRAIN (LIVE, ATTENUATED) PRODUCED IN HUMAN DIPLOID (MRC-5) CELLS are studying vaccine-related immune responses in children. One Phase 3 trial includes children and adolescents 0 to 18 years old after childhood cancer treatment and measures antibody changes after revaccination against chickenpox and measles. Another Phase 3 trial includes healthy children 12 to 15 months old and compares immune response and safety for different vaccine injection routes. The main outcomes are IgG antibody levels, seroresponse, and immune response at Day 43 in the healthy-children study. Both studies are authorised and focus on how well vaccination works in these target groups.
Trial overview
The available trials study RUBELLA VIRUS WISTAR RA 27/3 STRAIN (LIVE, ATTENUATED) PRODUCED IN HUMAN DIPLOID (MRC-5) CELLS as part of vaccine research in children.12 These studies focus on immune response, which means how the body makes protection after vaccination.12
Both trials are Phase 3 and are listed as Authorised.12 Phase 3 trials usually involve larger groups and help researchers learn how well a vaccine approach works in the study population.12
Target populations and conditions
One trial includes children and adolescents from 0 to 18 years old who have had childhood cancer.1 This study looks at revaccination after cancer treatment, because treatment can affect immune protection.1
The other trial includes healthy children 12 to 15 months of age.2 It studies vaccination in early childhood and focuses on varicella, which means chickenpox, and also on measles, mumps, and rubella immune responses.2
The conditions named in the trial data are pediatric cancer and varicella.12 In one study, the vaccine response to measles is also measured after treatment for childhood cancer.1
Study design and phase
Both studies are interventional, which means the researchers give a vaccine and then measure the results.12 This is different from an observational study, where researchers only watch what happens without assigning treatment.
The childhood cancer study plans to enroll 160 participants.1 The healthy-children study plans to enroll 944 participants.2 Larger enrollment can help researchers compare groups more reliably.
In the healthy-children study, researchers compare intramuscular injection, meaning into a muscle, with subcutaneous injection, meaning under the skin.2 The main goal is to see whether the intramuscular approach is not worse than the subcutaneous approach by a set margin, which is called non-inferiority.2
Main endpoints and outcome measures
In the childhood cancer trial, the main outcomes are the difference in VZ IgG antibody levels before and after revaccination against chickenpox and the difference in measles IgG antibody levels before and after revaccination against measles.1 IgG antibodies are blood markers that help show whether the immune system has built protection.
The brief summary for this trial says the main aim is to measure the proportion of patients with a protective VZ-IgG level after vaccination compared with before vaccination, and the same idea is used for morbilli-IgG, which refers to measles antibodies.1 This tells researchers whether revaccination improves immune protection after cancer treatment.1
In the healthy-children trial, the main outcomes are seroresponse to VZV gE at Day 43, anti-VZV gE IgG concentration at Day 43, seroresponse to MMR antigens at Day 43, and anti-measles, anti-mumps, and anti-rubella IgG concentration at Day 43.2 Day 43 is the time point used to check the blood response after vaccination.2
The study summary says the trial aims to show non-inferiority for the intramuscular route compared with the subcutaneous route for both the varicella-related vaccine and the MMR vaccine.2 In simple terms, the study asks whether the muscle injection works at least as well as the skin-under injection for immune response.2
What the trials compare
The childhood cancer study compares antibody levels before and after revaccination, so it is looking at change within the same type of patient group.1 The key question is whether children and adolescents after cancer treatment can regain protective immunity.
The healthy-children study compares different vaccine products and different injection routes.2 It includes an investigational chickenpox vaccine, called GSKVX000000025896 in the trial data, and a marketed measles, mumps and rubella vaccine.2
Because the trial data list several vaccine names, the study appears to examine how the immune system responds to the vaccines when given by different routes.2 The primary focus is not on symptoms, but on blood test results that show immune response.2
Patient-friendly explanation of key terms
Antibody means a protein made by the immune system that helps fight infection.12 When a trial measures antibody levels, it is checking how strong the body’s protection is.
Revaccination means getting a vaccine again after a previous treatment or earlier vaccination.1 In the cancer study, this is done after childhood cancer treatment to see if protection can be restored.
Seroresponse means the blood shows a clear rise in protective antibodies after vaccination.2 This is one way researchers measure whether the vaccine worked.
IgG concentration means the amount of a certain antibody in the blood.12 A higher level after vaccination can suggest better immune response.
GMC stands for geometric mean concentration, a way to summarize antibody levels in a group.2 Researchers use it to compare average immune response between study groups.